Download PDF
Thromb Haemost 1972; 27(03): 543-553
DOI: 10.1055/s-0038-1649394
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Activation of Hageman Factor by Cardiac Arrest

J. G. Latour Ph.D   *)
1   Department of Pathology, University of California School of Medicine, San Francisco General Hospital, San Francisco, Cal., U.S.A
,
D. G. McKay M. D.
1   Department of Pathology, University of California School of Medicine, San Francisco General Hospital, San Francisco, Cal., U.S.A
,
Mary H. Parrish B. S.
1   Department of Pathology, University of California School of Medicine, San Francisco General Hospital, San Francisco, Cal., U.S.A
› Author AffiliationsSupported by United States Public Health Service NIH Grant No. HE-12033 and GM-18470-01. Dr. Latour is a fellow of the “Medical Research Council of Canada55.
Further Information

Publication History

Publication Date:
24 July 2018 (online)

Also available at
    Permissions and Reprints

Summary

The induction of cardiac arrest in rabbits for a period of 3min, followed by reestablishment for the circulation, resulted in a 27 % decrease in circulating Hageman factor. The maximum depletion occurred within 30 to 60 min and normal levels were restored by 4 h. Anti-contact product activity remained unchanged. Circulating platelets dropped by 17 % and small arterial thrombi were found predominantly in the lungs. It is concluded that cardiac arrest followed by re-circulation of the blood causes activation of Hageman factor. The proximate mechanism of this activation in experimental generalized anoxemia remains to be determined. Administration of a potent glucocorticoid prior to cardiac arrest markedly inhibited activation of the clotting mechanism.

*) Present adress: Institut de Cardiologie de Montreal, 5000 Est, Rue Belanger, Montreal 410, Quebec, Canada.


 

  • References

  • 1 Aberg H, Gullhed I. Direct current countershock complications. Acta med. scand 183: 415 1968;
    PubMedGoogle Scholar
  • 2 Ashford T. P, Freiman D. G. Platelet aggregation at sites of minimal endothelial injury. An electron microscopic study. Amer. J. Pathol 53: 599 1968;
    PubMedGoogle Scholar
  • 3 Bell W. N, Alton H. G. A brain extract as a substitute for platelet suspensions in the thromboplastin generation test. Nature 174: 880 1954;
    CrossrefPubMedGoogle Scholar
  • 4 Blaisdell F. W, Lim R. C, Amberg J. R, Choy S. H, Hall A. D, Thomas A. N. Pulmonary microembolism: a cause of morbidity and death after major vascular surgery. Arch. Surg 93: 776 1966;
    CrossrefPubMedGoogle Scholar
  • 5 Cline M. J, Melmon K. L. Plasma kinins and corticol: possible explanation of anti-inflammatory action of cortisol. Science 153: 1135 1966;
    CrossrefPubMedGoogle Scholar
  • 6 Goon W. W, Hodgson P. E. Fibrinolysis in surgery patients. I. Possible relationship to a hemorrhagic diathesis. Surg. Gynecol. Obstet 95: 717 1952;
    PubMedGoogle Scholar
  • 7 Crowell J. W, Sharpe G. P, Lambright R. L, Read W. L. The mechanism of death after resuscitation following acute circulatory failure. Surgery 38: 696 1955;
    PubMedGoogle Scholar
  • 8 Dacie J. V, Lewis S. M. Practical Haematology. 3rd Edition.. 380 Churchill, London; 1963
    Google Scholar
  • 9 Fine J, Palmerio C, Rutenberg S. New developments in therapy of refractory traumatic shock. Arch. Surg 96: 163 1968;
    CrossrefPubMedGoogle Scholar
  • 10 Humphrey J. H, Toh G. G. Absorption of serotonin and histamine by dog platelets. J. Physiol 124: 300 1954;
    CrossrefPubMedGoogle Scholar
  • 11 Latour J. G, McKay D. G, Nasu K. Prevention by glucocorticoids of the generalized Shwartz- man reaction. (In preparation).
    PubMedGoogle Scholar
  • 12 Latour J. G, Renaud S. Prevention by glucocorticoids of various blood parameter changes following surgical intervention and endotoxin administration in the rat. Canad. med. Assoc. J 100: 20 1969;
    PubMedGoogle Scholar
  • 13 Lillehei R. C. A physiological approach to the treatment of endotoxin shock in the experimental animal. Arch. Surg 78: 464 1959;
    CrossrefPubMedGoogle Scholar
  • 14 Lillehei R. C, Longerbeam J. K, Bloch J. H. Physiology and therapy of bacteremic shock. Experimental and clinical observations. Amer. J. Cardiol 12: 599 1963;
    PubMedGoogle Scholar
  • 15 Lillehei R. G, Longerbeam J. K, Rosenberg J. C. The nature of irreversible shock: its relation to intestinal changes. In: Ciba Symposium on Shock. 106 Springer-Verlag; Heidelberg: 1961
    Google Scholar
  • 16 Lim R. C, Blaisdell F. W, Choy S. H, Hall A. D, Thomas A. N. Massive pulmonary microembolism in regional shock. Surg. Forum 17: 13 1966;
    PubMedGoogle Scholar
  • 17 Lim R. C, Blaisdell F. W, Goodman J. R, Hall A. D, Thomas A. N. Electron microscopic study of pulmonary microemboli in regional and systemic shock. Surg. Forum 18: 25 1967;
    PubMedGoogle Scholar
  • 18 Margolis J. Hageman factor and capillary permeability. Aust. J. exp. Biol. med. Sei. 37 : 239 1959;
    PubMedGoogle Scholar
  • 19 McKay D. G. Disseminated Intravascular Coagulation: An Intermediary Mechanism of Disease. P.B. Hoeber; New York: 1965
    Google Scholar
  • 20 McKay D. G, Latour J. G, Parrish M. H. Activation of Hageman factor by a-adrenergia stimulation. Thrombos. Diathes. haemorrh. (Stuttg) 23: 417 1970;
    PubMedGoogle Scholar
  • 21 McKay D. G, Whitaker A. N, Cruse V. Studies of catecholamine shock. II. An experimental model of microangiopathic hemolysis. Amer. J. Pathol 56: 177 1969;
    PubMedGoogle Scholar
  • 22 Melmon K. L, Cline M. J. Kinins. Amer. J. Med 43: 153 1967;
    CrossrefPubMedGoogle Scholar
  • 23 Muller-Berghaus G. Patho-physiology of disseminated intravascular coagulation. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl 36: 45 1969;
    PubMedGoogle Scholar
  • 24 Müller-Berghaus G, Davidson E, McKay D. G. Prevention of the generalized Shwartzman reaction in pregnant rats by a-adrenergic blockade. Effects on the coagulation mechanism. Obstet. Gynecol 30: 774 1967;
    PubMedGoogle Scholar
  • 25 Nagasawa S, Takahashi H, Koida M, Suzuki T. Partial purification of bovine plasma kallikreinogen, its activation by Hageman factor. Biochem. biophys. Res. Comm 32: 664 1968;
    CrossrefPubMedGoogle Scholar
  • 26 Niewiarowski S, Bankowski E. Interaction of the Hageman factor with insoluble collagen. Bull. Acad. pol. Sei 17: 137 1969;
    PubMedGoogle Scholar
  • 27 Nossel H. L. The Contact Phase of Blood Coagulation. 138-139 F.A. David, Philadelphia; 1964
    Google Scholar
  • 28 Nossel H. L, Niemetz J. A normal inhibitor of the blood coagulation contact reaction product. Blood 25: 712 1965;
    PubMedGoogle Scholar
  • 29 Packham M. A, Nishizawa E. E, Mustard J. F. Response of platelets to tissue injury. Biochem. Pharmacol. Suppl. 171 Pergamon Press; 1968
    Google Scholar
  • 30 Ratnoff O. D, Miles A. A. Induction of permeability-increasing activity in human plasma by activated Hageman factor. Brit. J. exp. Path 45: 328 1964;
    PubMedGoogle Scholar
  • 31 Renaud S, Allard C, Latour J. G. The prevention by glucocorticoids of endotoxin-initiated thrombosis in the rat, in relation to fibrinolysis, coagulation and lipemia. Amer. Heart J 72: 797 1966;
    CrossrefPubMedGoogle Scholar
  • 32 Renaud S, Latour J. G. Effect of prolonged glucocorticoid administration on lipemia, coagulation and thrombosis in rat. Proc. Soc. exper. Biol. (N. Y) 128: 32 1968;
    CrossrefPubMedGoogle Scholar
  • 33 Renaud S, Latour J. G. Prevention by a glucocorticoid of the thrombotic and hemorrhagic tendencies consecutive to shock and surgical intervention in rat. Thrombos. Diathes. haemorrh. (Stuttg) 21: 151 1969;
    PubMedGoogle Scholar
  • 34 Resnekov L, McDonald L. Appraisal of electroconversion in treatment of cardiac dysrhythmias. Brit. Heart J 30: 786 1968;
    CrossrefPubMedGoogle Scholar
  • 35 Resnekov L, McDonald L. Complications in 220 patients with cardiac dysrhythmias treated by phased direct current shock, and indications for electroconversion. Brit. Heart J 29: 92 1967;
    PubMedGoogle Scholar
  • 36 Schayer R. W, Kobayashi Y. Histidine decarboxylase and histamine binding in rabbit platelets. Proc. Soc. exper. Biol. (N. Y) 92: 653 1956;
    CrossrefPubMedGoogle Scholar
  • 37 Sheehan H. L, Davis J. C. Renal ischemia with failed reflow. J. Path. Bact 78: 105 1959;
    CrossrefPubMedGoogle Scholar
  • 38 Strock P. E, Majno G. Microvascular changes in acutely ischemic rat muscle. Surg. Gynecol. Obstet 129: 1213 1969;
    PubMedGoogle Scholar
  • 39 Whitaker A. N, McKay D. G. Induction of hypotension in Rhesus monkeys and rabbits by intravenous thrombin infusion. Lab. Invest 20: 79 1969;
    PubMedGoogle Scholar
  • 40 Whitaker A. N, McKay D. G, Csavossy I. Studies of catecholamine shock. I. Disseminated intravascular coagulation. Amer. J. Pathol 56: 153 1969;
    PubMedGoogle Scholar
  • 41 Wilner G. D, Nossel H. L, LeRoy E. C. Activation of Hageman factor by collagen. J. clin. Invest 47: 2608 1968;
    CrossrefPubMedGoogle Scholar
  • 42 Zucker M. B, Borrelli J. Quantity, assay and release of serotonin in human platelets. J. appl. Physiol 07: 425 1955;
    CrossrefPubMedGoogle Scholar
  • 43 Zucker M. B, Borrelli J. Relationship of clotting factors to serotonin release from washed platelets. J. appl. Physiol 07: 432 1955;
    CrossrefPubMedGoogle Scholar